因既往联合抗逆转录病毒治疗不耐受而换用利匹韦林/恩曲他滨/替诺福韦的成人HIV感染患者队列中的血脂变化与耐受性:PRO-STR研究
PRO-STR是一项48周前瞻性观察性批准后研究,纳入25家医院中病毒载量<1000拷贝/mL、既往联合抗逆转录病毒治疗至少12个月的HIV感染成人,换用利匹韦林/恩曲他滨/替诺福韦后,既往NNRTI组和PI/r组血脂谱均显著改善(HDL除外,呈非显著升高),不耐受显著减少。
要点
- 换用利匹韦林/恩曲他滨/替诺福韦后,既往NNRTI组和PI/r组总胆固醇、总胆固醇/HDL比值、LDL和甘油三酯均显著降低。
- HDL胆固醇在两组均呈非显著升高。
- NNRTI组最常见不耐受为神经精神类,PI/r组为胃肠道和代谢类,第48周两组均显著减少。
核心结论
- 在HIV感染患者队列中,从以NNRTI或PI为基础的方案换用利匹韦林/恩曲他滨/替诺福韦后,血脂谱改善且不耐受减少。
研究设计与样本
- PRO-STR是一项48周前瞻性观察性批准后研究,在25家医院开展。
- 纳入病毒载量<1000拷贝/mL、接受联合抗逆转录病毒治疗至少12个月且既往3个月剂量恒定的患者,按既往治疗分为NNRTI组或利托那韦增效PI(PI/r)组,共纳入303例患者(平均年龄46.6岁;男性74.0%;既往治疗NNRTI 74.7%、PI/r 25.3%)。
主要发现
- NNRTI组:总胆固醇基线195.5±38.4 mg/dL vs 第48周171.0±35.5 mg/dL;总胆固醇/HDL比值基线4.2±1.2 vs 第48周4.0±1.2;HDL基线49.1±12.0 mg/dL vs 第48周49.2±45.8 mg/dL;LDL基线119.2±30.2 mg/dL vs 第48周114.2±110.7 mg/dL;甘油三酯基线136.6±86.8 mg/dL vs 第48周113.4±67.8 mg/dL。
- PI/r组:总胆固醇基线203.2±48.8 mg/dL vs 第48周173.4±36.9 mg/dL;总胆固醇/HDL比值基线4.7±1.6 vs 第48周4.0±1.2;HDL基线46.4±12.5 mg/dL vs 第48周52.1±54.4 mg/dL;LDL基线127.0±36.3 mg/dL vs 第48周111.4±35.8 mg/dL;甘油三酯基线167.6±107.7 mg/dL vs 第48周122.7±72.1 mg/dL。
- NNRTI组神经精神类不耐受基线81.3% vs 第48周0.0%;PI/r组胃肠道不耐受基线48.7% vs 第48周0.0%,代谢类不耐受基线42.1% vs 第48周0.0%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To analyse lipid changes and tolerability in a cohort of HIV-infected patients who switched their antiretroviral regimens to rilpivirine/emtricitabine/tenofovir (RPV/FTC/TDF) in a real-world setting. METHODS: PRO-STR is a 48 week prospective observational post-authorization study in 25 hospitals. Patients with a viral load <1000 copies/mL, receiving at least 12 months of combination ART (cART), with constant posology for at least the prior 3 months, were categorized according to previous treatment [NNRTI or ritonavir-boosted PI (PI/r)]. Analytical tests were performed at the baseline visit, between week 16 and week 32, and at week 48. RESULTS: A total of 303 patients were included (mean age 46.6 years; male 74.0%; previous treatment 74.7% NNRTI and 25.3% PI/r). Both groups exhibited significantly reduced lipid profiles, except for HDL cholesterol, for which a non-significant increase was observed. [NNRTI patients: total cholesterol (baseline: 195.5 ± 38.4 mg/dL; week 48: 171.0 ± 35.5 mg/dL), total cholesterol/HDL ratio (baseline: 4.2 ± 1.2; week 48: 4.0 ± 1.2), HDL (baseline: 49.1 ± 12.0 mg/dL; week 48: 49.2 ± 45.8 mg/dL), LDL (baseline: 119.2 ± 30.2 mg/dL; week 48: 114.2 ± 110.7 mg/dL), and triglycerides (baseline: 136.6 ± 86.8 mg/dL; week 48: 113.4 ± 67.8 mg/dL); PI/r patients: total cholesterol (baseline: 203.2 ± 48.8 mg/dL; week 48: 173.4 ± 36.9 mg/dL), total cholesterol/HDL ratio (baseline: 4.7 ± 1.6; week 48: 4.0 ± 1.2), HDL (baseline: 46.4 ± 12.5 mg/dL; week 48: 52.1 ± 54.4 mg/dL), LDL (baseline: 127.0 ± 36.3 mg/dL; week 48: 111.4 ± 35.8 mg/dL), and triglycerides (baseline: 167.6 ± 107.7 mg/dL; week 48: 122.7 ± 72.1 mg/dL)]. The most common intolerances were neuropsychiatric in the NNRTI patients and gastrointestinal and metabolic in the PI/r patients, and these intolerances were significantly reduced in both groups at week 48 [NNRTI: neuropsychiatric (baseline: 81.3%; week 48: 0.0%); PI/r: gastrointestinal (baseline: 48.7%; week 48: 0.0%) and metabolic (baseline: 42.1%; week 48: 0.0%)]. CONCLUSIONS: RPV/FTC/TDF improved the lipid profiles and reduced the intolerances after switching from NNRTI or PI-based regimens, in a cohort of HIV-infected patients.
引用
- Ocampo A, Domingo P, Fernández P, et al. Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study. J Antimicrob Chemother. 2018. PMID: 29788066. doi:10.1093/jac/dky175
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。